The Promise of Once-Yearly Lenacapavir: A Game Changer in HIV Prevention
As Gilead Sciences prepares to launch their twice-yearly lenacapavir pre-exposure prophylaxis (PrEP), the pharmaceutical giant is also pushing the boundaries with once-yearly formulations. These innovative developments hold the potential to significantly contribute to ending the HIV epidemic. Researchers recently presented promising phase I data on two longer-lasting formulations at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and in The Lancet. The results were compelling enough to bypass phase II trials and move directly to phase III testing.
Long-Acting PrEP: A Step Toward More Effective HIV Prevention
Daily oral PrEP, while highly effective when taken consistently, poses challenges for many. Issues like adherence, stigma, and the inconvenience of daily pill-taking can deter some individuals from maintaining their treatment. Lenacapavir, an antiretroviral drug, blocks HIV replication. Unlike vaccines, which train the immune system, lenacapavir provides a direct pathway to prevent HIV infection. This positions it as an essential tool in the ongoing battle against HIV.
Dr. Renu Singh, Gilead’s director of clinical pharmacology, emphasized the potential impact of once-yearly intramuscular lenacapavir for PrEP. “Once-yearly intramuscular lenacapavir for PrEP has the potential to improve PrEP uptake and persistence and thus improve the scalability and public health impact of PrEP in populations who would benefit most,” Singh and her colleagues concluded.
How Lenacapavir Fits Into the Existing Landscape
Lenacapavir (Sunlenca) is approved for use in combination regimens for people with multidrug-resistant HIV. Its long half-life allows for infrequent administration, forming a depot below the skin that releases the drug over time. Studies showed that twice-yearly lenacapavir was highly effective in preventing HIV. In trials, this regimen demonstrated a 100% effectiveness in young cisgender women in Africa and reduced the risk of HIV by 96% in gay and bisexual men and gender-diverse individuals.
The Future of Once-Yearly Lenacapavir
Gilead’s recent phase I trial evaluated the pharmacokinetics, safety, and tolerability of two once-yearly formulations of lenacapavir. The trial involved 50 healthy adults who received a single 5,000 mg dose through two intramuscular injections. The formulations differed in ethanol content, with 5% and 10% concentrations reducing the viscosity of the injection.
Landmark Results and Implications
The results were remarkable. Lenacapavir plasma concentrations remained above the 95% effective concentration for at least 56 weeks. The highest median concentrations were well above the peak concentrations of the twice-yearly regimen. Most impressively, the once-yearly injections maintained effective drug levels throughout the study, indicating potential for a similarly high efficacy as the twice-yearly form.
Table: Comparison of Lenacapavir Formulations
| Metric | Once-Yearly (5% Ethanol) | Once-Yearly (10% Ethanol) | Twice-Yearly |
|---|---|---|---|
| Highest Median Concentration (ng/ml) | 247.0 | 336.0 | 67.3 |
| Median Trough Concentration at Week 52 (ng/ml) | 57.0 | 65.5 | 23.4 |
| Median AUC | Higher | Higher | Lower |
Preparing for Phase III Trials and Beyond
Gilead is planning a phase III trial of the once-yearly lenacapavir PrEP in the second half of 2025. The success of this trial will pave the way for possible US Food and Drug Administration approval in 2027. Dr. Joseph Eron, an HIV researcher and clinician, praised the development, noting that the simplicity of the formulation will make it accessible for manufacturing by generic companies in low-income countries.
Toward a World Without HIV
The mission to eradicate HIV is a global one, and lenacapavir is poised to play a crucial role. Gilead’s commitment to making lenacapavir accessible and affordable is already in motion, with plans to work with pharmaceutical manufacturers in more than 100 resource-limited countries. However, concerns over reduced US foreign aid programs, including PEPFAR, pose challenges to universal access.
Did you know?
Global PEPFAR Legacy:
- Between 2004 and 2022, PEPFAR reached over 5.7 million people with antiretroviral therapy (ART) for HIV/AIDS. The initiative has been a cornerstone in the global response to the epidemic.
FAQ: What You Need to Know About Lenacapavir
Q: How does lenacapavir work?
A: Lenacapavir is an antiretroviral drug that inhibits HIV replication, helping to prevent the virus from infecting healthy cells.
Q: What are the current formulations of lenacapavir?
A: Lenacapavir is available in a twice-yearly subcutaneous injection. Gilead is developing a once-yearly formulation, which shows promising results in clinical trials.
Q: Why is a once-yearly formulation significant?
A: A once-yearly formulation could improve adherence and provide more convenient treatment options, which are crucial for public health efforts in HIV prevention.
Pro Tips: Maximizing HIV Prevention
Adherence is Key: Ensure you take your PrEP consistently as prescribed to maintain effective protection.
Stay Informed: Keep up to date with the latest research and developments in HIV prevention and treatment.
Public Health Efforts: Support initiatives that enhance access to PrEP and other prevention tools for high-risk populations globally.
Leave your thoughts and comments in the section below, or share this article with others who might find it informative. Learn more about the latest developments on HIV epidemiology, such as <link text "incident HIV cases in South Africa"> and through our regularly updated content.
